ANIX (Anixa Biosciences) Cyclically Adjusted Revenue per Share: $0.00 (As of Apr. 2026)


ANIX Anixa Biosciences Inc ANIX
27 GF Score
Price $3.06
! 3 Warning Signs
View Full Analysis

What is Anixa Biosciences Cyclically Adjusted Revenue per Share?

Anixa Biosciences ANIX -6.73% 27 Cyclically Adjusted Revenue per Share is $0.00 as of Apr. 2026. GuruFocus rates ANIX with a GF Score™ of 27/100. The stock has 3 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Anixa Biosciences's adjusted revenue per share for the three months ended in Apr. 2026 was $0.000. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is $0.00 for the trailing ten years ended in Apr. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Anixa Biosciences was 20.80% per year. The lowest was -29.70% per year. And the median was -2.10% per year.

As of today (2026-07-06), Anixa Biosciences's current stock price is $3.06. Anixa Biosciences's Cyclically Adjusted Revenue per Share for the quarter that ended in Apr. 2026 was $0.00. Anixa Biosciences's Cyclically Adjusted PS Ratio of today is .

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Anixa Biosciences was 20.48. The lowest was 1.97. And the median was 12.06.


Anixa Biosciences  (NAS:ANIX) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Anixa Biosciences was 20.48. The lowest was 1.97. And the median was 12.06.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Anixa Biosciences Cyclically Adjusted Revenue per Share Related Terms


Anixa Biosciences Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Anixa Biosciences's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Anixa Biosciences Cyclically Adjusted Revenue per Share Chart

Anixa Biosciences Annual Data
Trend Oct16 Oct17 Oct18 Oct19 Oct20 Oct21 Oct22 Oct23 Oct24 Oct25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Anixa Biosciences Quarterly Data
Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24 Apr24 Jul24 Oct24 Jan25 Apr25 Jul25 Oct25 Jan26 Apr26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

ANIX vs BMEA, PMN, ATRA: Cyclically Adjusted Revenue per Share Comparison

For the Biotechnology subindustry, Anixa Biosciences's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anixa Biosciences Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anixa Biosciences's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Anixa Biosciences's Cyclically Adjusted PS Ratio falls into.


ANIX
27GF Score
Anixa Biosciences Inc ANIX
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Anixa Biosciences Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Anixa Biosciences's adjusted Revenue per Share data for the three months ended in Apr. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Apr. 2026 (Change)*Current CPI (Apr. 2026)
=0/333.0200*333.0200
=0.000

Current CPI (Apr. 2026) = 333.0200.

Anixa Biosciences Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201607 0.011 240.628 0.015
201610 0.023 241.729 0.032
201701 0.000 242.839 0.000
201704 0.000 244.524 0.000
201707 0.025 244.786 0.034
201710 0.000 246.663 0.000
201801 0.000 247.867 0.000
201804 0.045 250.546 0.060
201807 0.020 252.006 0.026
201810 0.000 252.885 0.000
201901 0.000 251.712 0.000
201904 0.013 255.548 0.017
201907 0.000 256.571 0.000
201910 0.000 257.346 0.000
202001 0.000 257.971 0.000
202004 0.000 256.389 0.000
202007 0.000 259.101 0.000
202010 0.000 260.388 0.000
202101 0.020 261.582 0.025
202104 0.000 267.054 0.000
202107 0.000 273.003 0.000
202110 0.000 276.589 0.000
202201 0.000 281.148 0.000
202204 0.000 289.109 0.000
202207 0.000 296.276 0.000
202210 0.000 298.012 0.000
202301 0.000 299.170 0.000
202304 0.007 303.363 0.008
202307 0.000 305.691 0.000
202310 0.000 307.671 0.000
202401 0.000 308.417 0.000
202404 0.000 313.548 0.000
202407 0.000 314.540 0.000
202410 0.000 315.664 0.000
202501 0.000 317.671 0.000
202504 0.000 320.795 0.000
202507 0.000 323.048 0.000
202510 0.000 0.000
202601 0.000 325.252 0.000
202604 0.000 333.020 0.000

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of $0.00 mean?
Anixa Biosciences (ANIX) has a Cyclically Adjusted Revenue per Share of $0.00 as of Apr. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Anixa Biosciences and its competitors.
Is Anixa Biosciences' Cyclically Adjusted Revenue per Share too high?
Anixa Biosciences' current Cyclically Adjusted Revenue per Share is $0.00. Overall, Anixa Biosciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Anixa Biosciences' Cyclically Adjusted Revenue per Share compare to BMEA and PMN?
Anixa Biosciences' Cyclically Adjusted Revenue per Share of $0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Biotechnology company?
A good Cyclically Adjusted Revenue per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Anixa Biosciences and its competitors. Anixa Biosciences's current Cyclically Adjusted Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anixa Biosciences stock overvalued right now?
Anixa Biosciences (ANIX) has a current Cyclically Adjusted Revenue per Share of $0.00. The current Cyclically Adjusted Revenue per Share is $0.00. Anixa Biosciences' overall GF Score™ is 27/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Anixa Biosciences (ANIX), the current Cyclically Adjusted Revenue per Share is $0.00 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Anixa Biosciences Business Description

Other Exchanges CY71:Germany
Address 3150 Almaden Expressway, Suite 250, San Jose, CA, USA, 95118
Anixa Biosciences Inc is a biotechnology company developing therapies and vaccines focused on critical unmet needs in oncology. Its operations are organized into reportable segments comprising Cancer Vaccines, CAR-T Therapies, and Other. The Cancer Vaccines segment involves vaccines to treat and prevent breast and ovarian cancer, as well as additional cancer vaccines targeting intractable cancers, including high-incidence malignancies in lung, colon, and prostate. The CAR-T Therapies segment involves the development of liraltagene autoleucel (lira-cel), an ovarian cancer immunotherapy using chimeric endocrine receptor-T cell technology, developed at its subsidiary, Certainty Therapeutics, Inc. The Other segment consists of legacy operations, including limited patent licensing activities.
27GF Score

Get the complete analysis for ANIX

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$3.06
Price